Higher	O
copeptin	B:C3489439
levels	O
are	O
associated	O
with	O
worse	O
outcome	O
in	O
patients	O
with	O
hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
.	O

Correlation	O
of	O
increased	O
copeptin	B:C3489439
levels	O
with	O
various	O
cardiovascular	B:C0007222
diseases	I:C0007222
has	O
been	O
described	O
.	O

The	O
clinical	O
use	O
of	O
copeptin	B:C3489439
levels	O
in	O
patients	O
with	O
hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
(	O
hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
)	O
has	O
not	O
been	O
investigated	O
before	O
.	O

In	O
this	O
study	B:C2603343
,	O
we	O
aimed	O
to	O
investigate	O
the	O
prognostic	B:C1511887
value	I:C1511887
of	O
copeptin	B:C3489439
levels	O
in	O
patients	O
with	O
hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
(	O
hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
)	O
.	O

hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
was	O
defined	O
as	O
presence	O
of	O
left	B:C0455826
ventricular	I:C0455826
wall	I:C0455826
thickness	I:C0455826
â‰¥	O
15	O
mm	O
in	O
a	O
subject	B:C0080105
without	O
any	O
concomitant	B:C0243087
disease	I:C0243087
that	O
may	O
cause	O
left	B:C0149721
ventricular	I:C0149721
hypertrophy	I:C0149721
.	O

Levels	O
of	O
copeptin	B:C3489439
and	O
plasma	O
N	O
-	O
terminal	O
probrain	O
natriuretic	O
peptide	O
(	O
NT	O
-	O
proBNP	O
)	O
were	O
evaluated	O
prospectively	O
in	O
24	O
obstructive	O
hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
patients	O
,	O
36	O
nonobstructive	O
hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
patients	O
,	O
and	O
36	O
age	O
-	O
and	O
sex	O
-	O
matched	O
control	O
subjects	O
.	O

Blood	B:C0178913
samples	I:C0178913
were	O
collected	O
in	O
the	O
morning	O
between	O
7	O
and	O
9	O
am	O
after	O
overnight	O
fasting	B:C0015663
.	O

Hospitalization	B:C0019993
with	O
diagnosis	B:C1704656
of	O
heart	B:C0018801
failure	I:C0018801
/	O
arrhythmia	B:C0003811
,	O
implantable	B:C0162589
cardioverter	I:C0162589
-	I:C0162589
defibrillator	I:C0162589
implantation	B:C0021107
,	O
and	O
cardiac	O
mortality	O
were	O
accepted	O
as	O
adverse	B:C1560249
cardiac	I:C1560249
events	I:C1560249
.	O

Copeptin	B:C3489439
and	O
NT	O
-	O
proBNP	O
levels	O
were	O
higher	O
in	O
the	O
hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
group	O
compared	O
with	O
controls	O
(	O
14.1	O
vs	O
8.4	O
pmol	O
/	O
L	O
,	O
P	O
<	O
0.01	O
;	O
and	O
383	O
vs	O
44	O
pg/	O
mL	O
,	O
P	O
<	O
0.01	O
,	O
respectively	O
)	O
.	O

Copeptin	B:C3489439
and	O
NT	O
-	O
proBNP	O
levels	O
were	O
higher	O
in	O
the	O
obstructive	O
hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
subgroup	B:C1515021
compared	O
with	O
the	O
nonobstructive	O
hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
subgroup	B:C1515021
(	O
18.3	O
vs	O
13.1	O
pmol	O
/	O
L	O
,	O
P	O
<	O
0.01	O
;	O
and	O
717	O
vs	O
223	O
pg/	O
mL	O
,	O
P	O
<	O
0.01	O
,	O
respectively	O
)	O
.	O

In	O
multivariable	O
logistic	O
regression	O
analysis	O
,	O
copeptin	B:C3489439
and	O
NT	O
-	O
proBNP	O
levels	O
remained	O
as	O
independent	O
predictors	O
of	O
heart	B:C0018801
failure	I:C0018801
(	O
P	O
<	O
0.01	O
for	O
both	O
)	O
and	O
adverse	B:C1560249
cardiac	I:C1560249
events	I:C1560249
(	O
P	O
<	O
0.01	O
for	O
both	O
)	O
.	O

Copeptin	B:C3489439
and	O
NT	O
-	O
proBNP	O
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
obstructive	O
hypertrophic	B:C0007194
cardiomyopathy	I:C0007194
,	O
and	O
higher	O
levels	O
were	O
associated	O
with	O
worse	O
outcome	O
.	O

